CT-G32 simultaneously targets four biological pathways, including GLP-1, making it what Celltrion describes as a potential first-in-class therapy. The company said the drug is designed to address persistent shortcomings of existing GLP-1 treatments — including inter-patient variability in weight loss, muscle loss, and durability — while maximizing fat reduction.
The ongoing toxicity study covers 252 rats and 48 monkeys to assess the compound's safety profile and establish appropriate clinical dosing ranges. Celltrion said it will also evaluate CT-G32's pharmacokinetic and pharmacodynamic properties alongside the toxicity assessments.
In earlier preclinical work, CT-G32 demonstrated superior weight loss compared to a reference compound at equivalent doses, while preserving lean body mass — a key differentiator in a market increasingly focused on muscle retention during treatment.
"CT-G32 is being developed as a next-generation drug that addresses the limitations of existing GLP-1-based therapies and extends beyond obesity to cover metabolic diseases," said a Celltrion spokesperson. The company is also developing an oral obesity drug in parallel, targeting an IND filing in the second half of 2028.
Copyright ⓒ Aju Press All rights reserved.
